TICKERNERD
Menu
DOCSDOCSHealthcare · Health Information Services

DOCS Stock Forecast: Doximity, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$27
+2.43% on the day

The 21 Wall Street analysts covering Doximity, Inc. hold a median 12-month price target of $28 — +5.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 17 Sept 2026 — in the upper half.

Market cap
$4.6B
Ticker Nerd rank
61 / 100
Median analyst target
$28
Analysts covering
21
Revenue$156.6M+7.3% y/y
Operating income$33.6M
Net income$24.3M
Free cash flow$39.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.5%
1M
+8.4%
YTD
−40.0%
1Y
−63.4%
From 52W high
−64.6%
From 52W low
+47.5%
$18
$75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DOCS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Doximity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Issuance
89
Accruals
81
Value
77
Revisions
45
Growth
43
Volatility
38
Size
23
Momentum
10

Quality (94): The business earns solid, repeatable profits on what it owns.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DOCS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DOCS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26DOCSHigh $47Median $28Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
8 Buy11 Hold2 Sell
Low $18Median $28High $47

The green dot is the last close — the median target sits +5.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
8 Sept 2026Freedom Capital MarketsDowngradeHold$24 → $27
21 Aug 2026BarclaysMaintainsEqual-Weight$20 → $27
21 Aug 2026BarclaysMaintainsEqual-Weight—
13 Aug 2026Truist SecuritiesMaintainsHold—
13 Aug 2026Truist SecuritiesMaintainsHold$19 → $24
10 Aug 2026Wells FargoDowngradeUnderweight—
10 Aug 2026Wells FargoDowngradeUnderweight$18
7 Aug 2026Evercore ISI GroupMaintainsIn-Line—
7 Aug 2026Evercore ISI GroupMaintainsIn-Line$22 → $40
7 Aug 2026JP MorganMaintainsNeutral—
7 Aug 2026JP MorganMaintainsNeutral$26 → $31
7 Aug 2026Piper SandlerReiteratesOverweight$42 → $47
7 Aug 2026Piper SandlerReiteratesOverweight—
29 June 2026B of A SecuritiesDowngradeUnderperform$38 → $20
29 June 2026B of A SecuritiesDowngradeUnderperform—
15 May 2026BarclaysDowngradeEqual-Weight—
15 May 2026Goldman SachsMaintainsNeutral—
14 May 2026BairdDowngradeNeutral—
14 May 2026BMO CapitalMaintainsMarket Perform—
14 May 2026BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DOCS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DOCS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, Doximity, Inc. returned −63.4% against +17.0% for the S&P 500, dividends included.

DOCS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26DOCSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DOCS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−5.6%
Analysts raising
0
Analysts cutting
18
Fundamentals

Doximity, Inc. (DOCS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.8×

Cheaper than 24% of US stocks

Price / sales
7.0×

Cheaper than 18% of US stocks

Price / book
5.1×

Cheaper than 20% of US stocks

EV / EBITDA
18.9×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
7.3%

Higher than 45% of US stocks

Earnings growth (YoY)
−54.4%

Higher than 9% of US stocks

Gross margin
84.9%

Higher than 94% of US stocks

Operating margin
21.5%

Higher than 81% of US stocks

Net margin
25.5%

Higher than 86% of US stocks

Returns & dividend
Return on equity
17.2%

Higher than 78% of US stocks

Return on assets
10.9%

Higher than 93% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Doximity, Inc. (DOCS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Doximity, Inc. has a market value of $4.6B and an enterprise value of $3.9B.

  • Revenue in the twelve months to 30 June 2026: $655.6M. The latest quarter grew 7.3% year on year.

  • Net income over the same four quarters: $167.0M, a 25.5% net margin.

  • Diluted earnings per share, trailing twelve months: $0.85.

  • Free cash flow in the twelve months to 30 June 2026: $297.0M.

  • Doximity, Inc. spent $400.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 179.8M.

  • Trailing P/E: 30.8×; forward P/E: 16.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Doximity, Inc. employs 880 people — $745K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Sept 2026

Data provided by Twelve Data

Peers

DOCS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
DOCSDoximity, Inc.$4.6B
61
WAYWaystar Holding Corp.$5.1B
34
HTFLHeartFlow, Inc.$4.3B
48
HNGEHinge Health, Inc.$7.3B
79
HQYHealthEquity, Inc.$8.1B
94
PRVAPrivia Health Group, Inc.$2.5B
66
SDGRSchrödinger, Inc.$2.3B
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Doximity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DOCS news & analysis

DOXIMITY, INC. (DOCS) INVESTOR ALERT Investors With Large Losses in Doximity, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

GlobeNewsWire · 17 Sept 2026negative

Bernstein Liebhard LLP announced that a shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired Doximity, Inc. common stock between August 8, 2024 and May 13, 2026. The law firm is inviting investors with large losses to contact them to discuss their rights.

Why it matters — A securities class action lawsuit has been filed against Doximity, which may be a concern for current and prospective shareholders of the company.

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law

Business Wire · 17 Sept 2026negative

SBS Law announced that investors in Doximity, Inc. have an opportunity to lead a securities fraud lawsuit against the company. The announcement, distributed via Business Wire, invites affected DOCS investors to participate in the legal action.

Why it matters — A securities fraud lawsuit against Doximity represents potential legal and reputational risk that DOCS investors may want to monitor.

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit

PRNewsWire · 17 Sept 2026negative

Rosen Law Firm announced a class action securities fraud lawsuit on behalf of purchasers of Doximity, Inc. common stock during the Class Period from August 8, 2024 to May 13, 2026. Investors have an opportunity to lead the lawsuit.

Why it matters — A securities fraud class action creates legal and reputational exposure for Doximity that could affect investor perception.

Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks Investment Research · 15 Sept 2026negative

Doximity (DOCS) shares closed at $25.81 in the latest trading session, falling 2.2% from the previous day. The decline was larger than the broader market's move during the same session.

Why it matters — A DOCS watcher would care because the stock underperformed the wider market in the session, signaling weaker-than-average price action for the company on that trading day.

Overworked Doctors Bet on AI to Boost Their Pay

Business Wire · 25 Aug 2026positive

Doximity released new survey data showing that physicians are optimistic about AI, with nearly a quarter expecting it to increase their compensation within the next year and two-thirds believing AI proficiency will provide a meaningful earnings edge over peers.

Why it matters — The findings highlight growing physician engagement with AI on Doximity's platform, which could signal increased usage and relevance for the company's services.

FAQ

Frequently asked questions about DOCS stock

What is the DOCS stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Doximity, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $47. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DOCS stock a buy right now?

Of the 21 analysts covering Doximity, Inc., 8 rate it a Buy, 11 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Doximity, Inc. 61 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DOCS?

As at 17 Sept 2026, Doximity, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will DOCS stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +5.4% from the last close, and Ticker Nerd's factor model ranks Doximity, Inc. 61 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DOCS stock forecast for 2030?

No analyst covering Doximity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DOCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $47 over the next 12 months.

How has DOCS stock performed over the past year?

Doximity, Inc. returned -63.4% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Doximity, Inc. do?

Doximity Inc. Class A Common Stock represents ownership in Doximity, a U.S.-based digital platform built for medical professionals.

What is the latest news on DOCS?

The most recent item we track (GlobeNewsWire, 17 Sept 2026): "DOXIMITY, INC. (DOCS) INVESTOR ALERT Investors With Large Losses in Doximity, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights". Bernstein Liebhard LLP announced that a shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired Doximity, Inc. common stock between August 8, 2024 and May 13, 2026. The law firm is inviting investors with large losses to contact them to discuss their rights.

Company

About Doximity, Inc.

Doximity Inc. Class A Common Stock represents ownership in Doximity, a U.S.-based digital platform built for medical professionals. Doximity provides cloud-based tools that help physicians, nurse practitioners, physician assistants, and medical students collaborate with colleagues, coordinate patient care, conduct virtual patient visits, access curated medical news and research, and manage careers and on-call schedules. The company focuses on healthcare communications and workflow software, serving the medical community through features designed for secure networking, telehealth support, and professional productivity. Doximity plays a notable role in the health information services market by connecting clinicians with tools that support day-to-day clinical coordination and access to specialty-specific information.

CEO Mr. Jeffrey A. Tangney · 880 employees · United States · https://www.doximity.com